98%
921
2 minutes
20
Patients with a Fontan circulation are at risk for chronic kidney disease (CKD), which is defined as persistently reduced glomerular filtration rate (GFR) <60ml/min/1.73 or elevated marker of kidney injury such as urinary albumin-to-creatinine ratio (UACR) >30mg/g. We determined the prevalence of albuminuria in patients with a Fontan circulation. The MEDLINE, EMBASE, Trip, and Cochrane databases were searched for studies reporting the prevalence of albuminuria in Fontan patients. Case reports, reviews, and univentricular patients pre-Fontan completion or post-heart transplantation were excluded. Studies were assessed for potential confounders and measurement, patient selection, intervention, and reporting biases, reported in a table. After systematic review, the pooled prevalence of albuminuria was calculated using the quality effects model for meta-analysis. Secondary outcomes were the clinical determinants of albuminuria. Thirteen studies were included in the systematic review, of which 11 were included in the meta-analysis (6 prospective, sample size per study 25-195 patients, 873 patients in total). The pooled prevalence of albuminuria was 28.4% (95% confidence interval 23.5-33.5%). GFR was mostly preserved in these patients. Albuminuria was associated with elevated systemic venous pressure in 5 studies. Other associations were inconclusive. The main limitations of our study are the predominantly retrospective and cross-sectional nature of the included studies with small sample sizes and heterogeneous study populations. Our findings show albuminuria is more prevalent than reduced GFR in patients with a Fontan circulation, implicating the potential value of UACR in addition to GFR when screening for CKD in these patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00246-024-03736-x | DOI Listing |
J Prim Care Community Health
September 2025
Division of Nephrology, Department of Medicine, National University Hospital, Singapore.
Background: Chronic kidney disease (CKD) management was largely centered around renin-angiotensin-aldosterone system inhibitors (RAASi) optimization, until recent emergence of novel therapeutics. However, slow adoption of guideline-directed therapy leaves patients vulnerable to disease progression. In 2022, a data-driven informatics approach was introduced to track real-time adherence to best practices.
View Article and Find Full Text PDFBr J Cancer
September 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Background: Studies examining the association of chronic kidney disease (CKD) with cancer risk have demonstrated conflicting results.
Methods: This was an individual participant data meta-analysis including 54 international cohorts contributing to the CKD Prognosis Consortium. Included cohorts had data on albuminuria [urine albumin-to-creatinine ratio (ACR)], estimated glomerular filtration rate (eGFR), overall and site-specific cancer incidence, and established risk factors for cancer.
Chronic kidney disease (CKD) is a growing public health concern globally, with primary care physicians (PCPs) playing a pivotal role in its early detection and management. This review explores the epidemiology, risk factors, screening strategies, and clinical manifestations of CKD within primary care settings. PCPs are integral in recognizing at-risk populations, initiating timely screening through eGFR and albuminuria tests, and managing modifiable risk factors like hypertension and diabetes.
View Article and Find Full Text PDFPrim Care Diabetes
October 2025
University of British Columbia, Vancouver, Canada.
This paper reports the expert opinions and recommendations made by primary care physicians (PCPs) to optimize screening and management of chronic kidney disease (CKD) associated with diabetes and presents algorithms to provide a practical and simplified guide for PCPs. Individuals living with type 2 diabetes (T2D) should be screened early and at regular intervals for CKD using both estimated glomerular filtration rate and urinary albumin-to-creatinine ratio testing. The risk of CKD assessed using the Kidney Disease: Improving Global Outcomes heatmap should be reviewed at least annually to optimize treatment to slow progression of CKD.
View Article and Find Full Text PDFMedicine (Baltimore)
August 2025
Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Renal dysfunction causes dyslipidemia, and the progression of kidney disease is associated with treatment-requiring lipid disorders. However, there is little data on the association between the severity of dyslipidemia and various treatment modalities with renal function. A total of n = 214 prevalent patients from a lipidology and nephrology practice were investigated in an unicentric cross-sectional study and divided into 4 groups based on the severity and therapeutic regimen of an existing lipid metabolism disorder: a lipid apheresis-treated group (LA), a drug-treated group (MG), a control group (CG) that included patients with lipid disorder not needing any treatment, and a diabetes group that comprised all diabetes patients.
View Article and Find Full Text PDF